Influence of cholestyramine on the pharmacokinetics of cerivastatin

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 6, 1997, Pages 250-254

  Muck W ^a   Ritter, W ^a   Frey, R ^a   Wetzelsberger, N ^b   Lucker P W ^b   Kuhlmann, J ^a  

^a BAYER AG   (Germany)

^b IKP Bobenheim ^*  (Germany)

Author keywords

Absorption; Bile acid sequestering agent; Cerivastatin; Cholestyramine; HMG CoA reductase inhibitor; Pharmacokinetic interaction

Indexed keywords

CERIVASTATIN; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANION EXCHANGE RESINS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD SPECIMEN COLLECTION; CHOLESTYRAMINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INHIBITORS; FASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIDINES;

EID: 1842290969     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Angerbauer R, Bischoff H, Steinke W, Ritter W 1994 BAY w 6228. Drugs Future 19: 537-541
2. Desager JP, Horsmans Y 1996 Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet 31: 348-371
3. Krol GJ, Beck GW, Ritter W, Lettieri JT 1993 LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 11: 1269-1275
4. Mazzu A, Lettieri J, Kaiser L, Frey R, Heller AH 1993 Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 53: 230
5. Mazzu A, Lettieri J, Heller AH 1997 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Abstract accepted for the 68th Meeting of the European Atherosclerosis Society (EAS), May 7-10, Brügge, Belgium
6. Mück W, Ritter W, Ochmann K, Kuhlmann J 1997 Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol 35: 255-260
7. Nakai A, Nishikata M, Matsuyama K, Ichikawa M 1996 Drug interaction between simvastatin and cholestyramine in vitro and in vivo. Biol Pharm Bull 19: 1231-1233
8. Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, Brescia D 1990 Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolaemia. Clin Pharmacol Ther 48: 201-207
9. Ritter W, Frey R, Krol G, Kuhlmann J 1993 Rivastatin single dose pharmacokinetics. Clin Pharmacol Ther 53: 210
10. Smith HT, Jakubaitis LA, Troendle AJ, Hwang DS, Robinson WT 1993 Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 6: 375S-382S
11. Welling PG 1984 Interactions affecting drug absorption. Clin Pharmacokinet 9: 404-434